HIV/AIDS Clinical Care: Archives

SUMMARY AND COMMENT

PEP in a High-Prevalence Setting

• May 18, 2009
• Sonia Nagy Chimienti, MD

A program in western Kenya demonstrates the many challenges of successfully implementing PEP.

• Reviewing:
• Siika AM et al., J Acquir Immune Defic Syndr 2009 May 1; 51:47

ANTIRETROVIRAL ROUNDS

When Your Patient Is Too Busy to Take MedsFree

• May 18, 2009

Two experts describe how they would encourage adherence in an AIDS patient already overburdened with work and family responsibilities.

SUMMARY AND COMMENT

Abacavir/3TC vs. Tenofovir/FTC . . . Again

• May 18, 2009
• Graeme Moyle, MBBS, MD

The latest switch study of these two NRTI backbones suggests that they offer comparable efficacy, with only modest differences in safety events.

• Reviewing:
• Martínez E et al., J Acquir Immune Defic Syndr 2009 Apr 24

AIDS WATCH

Lopinavir/r Preferred for Children Exposed to Nevirapine at BirthFree

• May 18, 2009

Children who receive single-dose nevirapine at birth may have better rates of virologic suppression with subsequent antiretroviral regimens that contain lopinavir/ritonavir than with those that . . .

• Reviewing:
• 2009 May 6

SUMMARY AND COMMENT

Lopinavir/r Appears Safe at All Stages of Pregnancy

• May 11, 2009
• Abigail Zuger, MD

The risk for birth defects does not appear to be elevated among pregnant women exposed to lopinavir/ritonavir, even during the first trimester.

• Reviewing:
• Roberts SS et al., J Acquir Immune Defic Syndr 2009 Apr 18

SUMMARY AND COMMENT

HIV Infection, CRP Levels, and MI Risk

• May 11, 2009
• Keith Henry, MD

HIV infection and elevated CRP levels each double the risk for heart attack, according to registry data from a large U.S. healthcare system.

• Reviewing:
• Triant VA et al., J Acquir Immune Defic Syndr 2009 Apr 21

SUMMARY AND COMMENT

Lipid Changes Differ Within HIV Drug Classes

• May 11, 2009
• Paul E. Sax, MD

In a pooled analysis of clinical trials, tenofovir-based therapies and those containing efavirenz or ritonavir-boosted atazanavir, darunavir, or saquinavir had the most favorable effects on plasma lipids.

• Reviewing:
• Hill A et al., HIV Clin Trials 2009 Jan/Feb; 10:1

SUMMARY AND COMMENT

Simplification of ARTFree

• May 11, 2009
• Sonia Nagy Chimienti, MD

In a U.S. clinical trial, patients who had never failed ART and switched to once-daily efavirenz/tenofovir/FTC maintained virologic suppression at the same rate as those who continued their baseline regimens.

• Reviewing:
• DeJesus E et al., J Acquir Immune Defic Syndr 2009 Apr 7

SUMMARY AND COMMENT

Ritonavir-Boosted Saquinavir Is Comparable to Lopinavir/r in Treatment-Naive Patients

• May 4, 2009
• Paul E. Sax, MD

Ritonavir-boosted saquinavir was noninferior to lopinavir/r in an international trial but currently offers few advantages over other PIs.

• Reviewing:
• Walmsley S et al., J Acquir Immune Defic Syndr 2009 Apr 1; 50:367

NEWS IN CONTEXT

Swine-Origin Influenza A (H1N1) and HIVFree

• May 4, 2009
• Carlos del Rio, MD, and Juan Sierra-Madero, MD

The CDC offers guidance for HIV-infected patients potentially exposed to swine flu.

• Reviewing:
• Centers for Disease Control and Prevention (CDC)., 2009 April 30